Companies are seeking to capitalize on a hot new gene technology, though a high-stakes patent dispute has yet to been settled. The gene-editing tool, known as Crispr-Cas9, serves as a kind of multipurpose molecular scissors that can cut DNA.
from WSJ.com: US Business http://ift.tt/2dnJZTU
via IFTTT
No comments:
Post a Comment